Starting four kidney-protective medicines together for type 2 diabetes
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether starting four recommended medications all at once—instead of one by one—is safe and better for protecting the kidneys in people with type 2 diabetes and early kidney damage. You would receive all four medicines together and be closely monitored by the study team.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 84 years old.
- You have type 2 diabetes.
- Your kidneys are still working fairly well (not severe kidney failure), but you have protein in your urine, a sign of kidney damage.
- You are currently taking no more than 2 recommended diabetes/kidney medications.
- You are able to take all four study medications (no history of allergies or bad reactions to them).
- Your blood pressure is not too low (systolic blood pressure above 90 mmHg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a computer program can help doctors choose the best medicines for people with type 2 diabetes who also have kidney or heart problems. The goal is to improve overall health by making sure patients receive treatments that are proven to help.
This study tests whether a goal-directed treatment plan using several medications can lower the risk of kidney and heart problems for people with diabetes and kidney disease. It aims to help you manage your condition more effectively.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
This study tests a combination of four medicines to see if they can better protect the kidneys in people with type 2 diabetes and kidney disease. It may help slow down kidney damage and reduce the amount of protein in urine.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.